Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China
Authors' conclusion
Anti-SAE+DM is characterized with a lower mortality rate and the development of malignancies being the primary cause of death. Patients who survived showed notable cutaneous damage, while the interstitial lung disease tends to stabilize.
Study context
- Population
- Patients with anti-SAE+ DM, four tertiary referral centres in China, March 2005–December 2022
- Participants
- 38 patients
- Outcome
- Long-term survival (all-cause death)
Methodological detailsmulticentre, inception cohort, unsupervised cluster analysis
- Multicentre
- Inception cohort
- Unsupervised cluster analysis
Main finding
As reported in the abstract
All-cause death
All-cause death, all patients
10.5%
4/38
Deaths from malignancies (at 13, 18 and 36 months)
3
Drug-free remission
35.3%
Observational data: associations, not effects.
Further findings
Organ damage (Myositis Damage Index) in surviving patients
- Damage to different systems
- 70.6%
- Skin damage
- 47.1%
- Skin rashes improved significantly with time (Cutaneous Disease Area and Severity Index)
Anti-SAE+DM-associated ILD on repeat CT · 6 and 12 months
- Patients with repeat CT
- 9
- Marked radiological improvement at 6 months or stable after 12 months
Unsupervised cluster analysis
- Three clusters with different characteristics and outcomes
- 3
Original publication
Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China. Rheumatology (Oxford). Published 22 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →